CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on January 23, 2020
VANCOUVER, Washington, Jan. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO
140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer will present a
comprehensive overview of the Company’s clinical, regulatory and commercialization priorities at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on Thursday, January 23, 2020 at 12:30
p.m. ET / 9:30 a.m. PT.
Date: | Thursday, January 23, 2020 |
Time: | 12:30 p.m. ET / 9:30 a.m. PT |
Access: | |
Via online: | https://www.wallstreetreporter.com/next-superstock-online-investor-con ... |
Via telephone: | +1 (213) 929-4232; Access code: 417-143-693 |
The livestream presentation will be archived for 30 days and participants are encouraged to go to the above-referenced website 10 minutes prior to the start of the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee.
Lesen Sie auch
About CytoDyn
CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5
appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses,
such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced
patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in 2019 for that indication. CytoDyn is
also conducting a Phase 3 investigative trial with leronlimab (PRO 140) as a once-weekly monotherapy for HIV-infected patients and, plans to initiate a registration-directed study of leronlimab
monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab (PRO 140) can significantly reduce viral
burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent
viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate
leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.